Cyclin Dependent Kinase 2 (CDK2) Inhibitors in Oncology Clinical Trials: A Review
Cyclin dependent kinase 2 (CDK2) is responsible for enforcing progression through the G1-S phase transition. Mutations and alterations in the CDK2 signaling pathway are associated with various cancers, most commonly breast, ovarian, prostate, leukemia, and lymphoma. CDK2 inhibitors have shown promis...
Salvato in:
| Autori principali: | , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Innovative Healthcare Institute
2025-01-01
|
| Serie: | Journal of Immunotherapy and Precision Oncology |
| Soggetti: | |
| Accesso online: | https://jipo.org/doi/pdf/10.36401/JIPO-24-22 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|